Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract introduces TrichoFoam™, a new foaming vehicle for compounding pharmacies, designed to be a gentle, non-irritating option for alopecia treatment, acknowledging that current topical treatments are limited and oral products may cause adverse effects.

This article reviews historical reports of skin changes, such as pseudoacanthosis nigricans, associated with cholesterol-lowering drugs like triparanol and nicotinic acid, but presents no new clinical findings.

This study found that oral tetracycline hydrochloride significantly reduced the free fatty acid/triglyceride ratio in hair lipids of young men and women treating acne vulgaris, with or without additional ethyl lactate application.

In this study, researchers developed a new prostate cancer imaging agent, a [99m Tc]tricarbonyl complex derived from finasteride, which demonstrated high radiochemical purity and significant uptake in the prostate of a rat model, suggesting its potential for noninvasive prostate cancer imaging.

In this study, two patients with severe alopecia areata who did not respond well to oral tofacitinib showed more than 50% hair regrowth after a single dose of intramuscular triamcinolone acetonide.

This study evaluated the stability of multiple active ingredients in TrichoSol™ for use in alopecia treatments, finding varying stability durations at room temperature—up to 180 days for some ingredients—supporting its use as a compounding vehicle in personalized therapies.

This study found that treatment with the polyphenolic compound TCQA activated β-catenin, promoting hair regrowth and the initiation of the anagen phase in mice and human dermal papilla cells.

This study found that ethanol and petroleum ether extracts of Tridax procumbens roots demonstrated significant antibacterial activity against various bacterial strains compared to benzene extracts.

This review discusses the potential of using triads of repositioned medicines targeting multiple pathogenic mechanisms to prevent or delay retina degeneration, but reports no new results.

This study showed that intralesional injections of pentoxifylline may be an effective and safe alternative to triamcinolone acetonide for treating localized alopecia areata.

This study developed a low-viscosity triamcinolone acetonide serum, used with a derma stamp microneedling device, to improve targeted treatment of alopecia areata, reporting favorable drug solubility, spreadability, and permeation to hair follicles, while maintaining skin safety.

In this study, acetone was not superior to other degreasers for enhancing the efficacy of trichloroacetic acid peels, and its higher flammability suggests using alternative degreasers to reduce workplace hazards.

This study found that intralesional vitamin D3 achieved similar effectiveness to triamcinolone acetonide for treating patchy alopecia areata but was associated with fewer adverse effects and higher patient satisfaction.

This review outlines the phytochemical composition and pharmacological potential of Tridax procumbens, a plant traditionally used in various regions for its purported medical benefits, including antioxidant, antimicrobial, and anti-inflammatory effects, among others.

This study reported that newly synthesized phenanthridin-3-one derivatives effectively inhibit human steroid 5-α-reductase.

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

This study associated ivory-colored areas observed through trichoscopy with steroid deposits in the dermis among patients with steroid-induced atrophy on the scalp.

In this study, Diane was reported to effectively treat acne, seborrhoea, androgenic alopecia, and mild hirsutism in hirsute women, with its effectiveness influenced by the severity and duration of the condition.

This study found that a novel thiohydantoin derivative, 3a, effectively inhibited androgen receptor activity in LNCaP cells and showed promising in vivo results by reducing testosterone-induced prostate changes, outperforming finasteride in mitigating prostate index and histopathological alterations.

This study developed a new triamcinolone acetonide serum combined with a microneedling device, showing promise for treating alopecia areata by targeting hair follicles in a less invasive, patient-friendly way with confirmed drug solubility, compatibility, and safety.

The authors of this meta-analysis suggest that intralesional injections of methotrexate and vitamin D3 may serve as safe and effective alternatives to triamcinolone acetonide for treating localized alopecia areata in adults, with trichoscopy aiding early detection of treatment effects.

This study reports the development of novel 4-amido-Δ4,6-steroids as potential inhibitors of 5α-reductase, showing promising in vitro results for conditions like acne and benign prostatic cancer.

This study found that abietic acid from pine resin more effectively inhibits testosterone 5α-reductase than several plant extracts, suggesting potential for treating androgen-dependent diseases.

In this study, polymeric micelles containing retinoic acid were found to improve targeted delivery to hair follicle structures in human skin more efficiently than a marketed retinoic acid gel, suggesting potentially safer and more effective acne treatment.

This study suggests that dietary decanoic acid may manage hyperandrogenism and insulin resistance in PCOS, as observed in animal and cell model experiments.

This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.